#ES­MO22: Adap­ti­m­mune touts new PhI da­ta for its cell ther­a­py treat­ment

As the cell ther­a­py biotech Adap­ti­m­mune has been ea­ger to present da­ta to progress with the FDA, the com­pa­ny hopes that its lat­est show­ing at ES­MO will be­gin to im­press reg­u­la­tors and in­vestors.

On Fri­day, the UK biotech pre­sent­ed the newest Phase I SUR­PASS tri­al da­ta for its MAGE-A4 cell ther­a­py pro­gram.

The tri­al had 44 pa­tients who re­ceived a sin­gle dose of the ther­a­py with 43 able to be eval­u­at­ed. Ad­di­tion­al­ly, 25 pa­tients had late-stage ovar­i­an, urothe­lial and head and neck can­cer. Here, the biotech saw 11 pa­tients re­spond, good for a 44% ob­jec­tive re­sponse rate.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER